Novartis CEO: Firm to Avoid US Tariffs by Mid-2026

Novartis CEO Outlines Strategy to Avert US Tariff Impact

Novartis CEO Vas Narasimhan announced at the World Economic Forum in Davos that the pharmaceutical company expects to be shielded from upcoming U.S. tariffs by the middle of 2026. The strategy relies on localizing production and managing inventory to serve the American market directly from within the country.

Tariff Landscape and Corporate Strategy

The announcement comes as the U.S. plans to impose tariffs of 10% on several European nations, scheduled to increase to 25%. Narasimhan stated Novartis has been proactive by investing in regional supply chains, a part of its previously announced $23 billion manufacturing investment. He also mentioned a potential agreement with the U.S. government that would exclude the company from such duties.

Mitigating Financial and Operational Risks

By producing in the U.S. for the U.S., Novartis aims to neutralize the financial impact of trade disputes, enhancing its operational stability. This strategic move future-proofs the company against potential policy shifts, positioning it favorably compared to competitors more exposed to international trade volatility. The company confirmed it has contingency plans in place.

Conclusion: Proactive Measures for Supply Chain Resilience

Novartis is taking decisive steps to insulate its operations from geopolitical trade tensions. By localizing its supply chain for the U.S. market, the company aims to maintain stable operations and financial performance, regardless of how tariff policies evolve.

FAQ

Q: How does Novartis plan to avoid U.S. tariffs?
A: The company plans to utilize its U.S.-based manufacturing facilities to supply the U.S. market, maintain sufficient inventory, and leverage a potential agreement with the U.S. government.

Q: What are the proposed U.S. tariffs?
A: The U.S. has announced plans for a 10% tariff on several European countries, set to increase to 25%.

Source: Investing.com